GlassScriptPhysician profile
Catherine M Vasko
NPI 1265672240
$2,240.84
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $1,510 · 2023: $219 · 2024: $33.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $328.78 | 2021-2023 | Tukysa |
| Celgene Corporation | $241.80 | 2022-2024 | Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $234.99 | 2021-2023 | |
| Janssen Biotech, INC. | $182.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $131.68 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $104.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.01 | 2021-2022 | |
| Genzyme Corporation | $64.62 | 2021-2022 | |
| Coherus Oncology, INC. | $61.47 | 2021-2022 | |
| Abbvie INC. | $58.66 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.72 | 2021-2022 | |
| Lilly USA, LLC | $47.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.69 | 2022 | |
| Incyte Corporation | $45.45 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.74 | 2021-2022 | |
| Morphosys, US INC. | $44.14 | 2022 | |
| Aveo Pharmaceuticals, INC. | $33.80 | 2021 | |
| Emd Serono, INC. | $27.14 | 2022 | |
| Beigene USA, INC. | $26.24 | 2022 | |
| Glaxosmithkline, LLC. | $25.88 | 2022 | |
| Blueprint Medicines Corporation | $24.77 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.75 | 2021 | |
| Gilead Sciences, INC. | $24.66 | 2022 | |
| Acrotech Biopharma INC. | $23.85 | 2021 | |
| Rigel Pharmaceuticals, INC. | $21.79 | 2022 | |
| Tg Therapeutics, INC. | $20.89 | 2022 | |
| Astellas Pharma US INC | $20.36 | 2021 | |
| Adaptive Biotechnologies Corporation | $19.83 | 2022 | |
| Organon LLC | $18.06 | 2022 | |
| Foundation Medicine, INC. | $17.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.23 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.22 | 2021 | |
| Puma Biotechnology, INC. | $15.47 | 2022 | |
| Eisai INC. | $14.33 | 2022 | |
| Cti Biopharma Corp. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Vasko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.